

June 30, 2006

## **Astellas Discontinues Development of Immunosuppressant FK778**

Japan, June 30, 2006 - Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori, hereinafter “Astellas”) today announced that it has decided to discontinue development of FK778, an immunosuppressant.

Astellas started Phase-II trials for FK778 for organ transplants in combination with Prograf<sup>®</sup> in the US and Europe. After careful review of the Phase-II clinical data on FK778, however, Astellas has decided to discontinue further development of FK778 in organ transplantation since the data reviewed did not indicate clear benefits over current treatment options in combination with Prograf<sup>®</sup>.

We have been committed to immunology and the transplant community and will continue our leading edge research and development program, exploring new treatment options that provide meaningful advancement over current therapies for years to come.

#####

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201    Fax: +81-3-5201-7473 <a href="http://www.astellas.com">http://www.astellas.com</a>